Pacific Stock Analysis

PACB
 Stock
  

USD 10.80  0.05  0.47%   

The current price rise of Pacific Biosciences may encourage investors to take a closer look at the company as it is trading at a share price of 10.80 on 1,581,507 in trading volume. The company executives may have good odds in positioning the company resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.89. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Pacific Biosciences partners.
Please check Your Equity Center.
  
The Pacific Biosciences stock analysis report makes it easy to digest most publicly released information about Pacific Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Pacific Stock analysis module also helps to analyze the Pacific Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Pacific Stock Analysis Notes

About 89.0% of the company shares are owned by institutional investors. The book value of Pacific Biosciences was at this time reported as 2.77. The company has Price/Earnings (P/E) ratio of 197.88. Pacific Biosciences recorded a loss per share of 0.84. The entity had not issued any dividends in recent years. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Pacific Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 728 people. To find out more about Pacific Biosciences contact Christian MBA at 650 521 8000 or learn more at https://www.pacb.com.

Pacific Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Pacific Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Pacific Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Pacific Biosciences is way too risky over 90 days horizon
Pacific Biosciences appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 130.51 M. Net Loss for the year was (181.22 M) with profit before overhead, payroll, taxes, and interest of 59.17 M.
Pacific Biosciences currently holds about 834.34 M in cash with (111.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69.
Pacific Biosciences has a frail financial position based on the latest SEC disclosures
Over 89.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Managements Discussion and Analysis of Financial Condition and Results of Operations - Marketscreener.com

Pacific Biosciences Upcoming and Recent Events

Earnings reports are used by Pacific Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pacific Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End9th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Pacific Largest EPS Surprises

Earnings surprises can significantly impact Pacific Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-02-01
2017-12-31-0.2-0.180.0210 
2015-08-05
2015-06-30-0.14-0.16-0.0214 
2022-02-15
2021-12-31-0.28-0.31-0.0310 
View All Earnings Estimates

Pacific Biosciences Thematic Classifications

In addition to having Pacific Biosciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Aggressive Defence
Small capitalization, high growth potential companies

Pacific Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pacific Biosciences's market, we take the total number of its shares issued and multiply it by Pacific Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Pacific Profitablity

Pacific Biosciences' profitability indicators refer to fundamental financial ratios that showcase Pacific Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Pacific Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Pacific Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Pacific Biosciences' profitability requires more research than a typical breakdown of Pacific Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.08) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.02.
Last ReportedProjected for 2022
Return on Investment(20.81) (22.45) 
Return on Average Assets(14.97) (16.15) 
Return on Average Equity(32.18) (34.71) 
Return on Invested Capital(0.65) (0.71) 
Return on Sales(1.03) (1.11) 

Management Efficiency

The entity has return on total asset (ROA) of (0.0926) % which means that it has lost $0.0926 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.4078) %, meaning that it created substantial loss on money invested by shareholders. Pacific Biosciences management efficiency ratios could be used to measure how well pacific biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2022, Return on Investment is expected to decline to -22.45. In addition to that, Return on Average Assets is expected to decline to -16.15. Pacific Biosciences Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 2.01 Billion. The current year Current Assets is expected to grow to about 1.2 B, whereas Return on Average Assets are forecasted to decline to (16.15) .
Last ReportedProjected for 2022
Book Value per Share 0.41  0.44 
Enterprise Value over EBIT(9.00) (9.71) 
Enterprise Value over EBITDA(10.26) (11.07) 
Price to Book Value 16.47  17.77 
Tangible Assets Book Value per Share 0.87  0.89 
Enterprise Value938.1 M801.3 M
Tangible Asset Value133.2 M137 M

Technical Drivers

As of the 1st of December, Pacific Biosciences holds the Semi Deviation of 5.23, risk adjusted performance of 0.258, and Coefficient Of Variation of 595.13. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacific Biosciences, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Pacific Biosciences, which can be compared to its competitors. Please check Pacific Biosciences information ratio, value at risk, and the relationship between the standard deviation and treynor ratio to decide if Pacific Biosciences is priced some-what accurately, providing market reflects its current price of 10.8 per share. Given that Pacific Biosciences has jensen alpha of 0.9361, we recommend you to check out Pacific Biosciences's recent market performance to make sure the company can sustain itself at a future point.

Pacific Biosciences Price Movement Analysis

The output start index for this execution was eighteen with a total number of output elements of fourty-three. Pacific Biosciences Triple Exponential Moving Average indicator shows smoothing effect of Pacific Biosciences price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Pacific Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacific Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacific Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacific Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kim Susan G over a month ago via Macroaxis 
Sale by Kim Susan G of 12968 shares of Pacific Biosciences
Christian Henry over two months ago via Macroaxis 
Sale by Christian Henry of 91307 shares of Pacific Biosciences
Eidel Jeff over two months ago via Macroaxis 
Pacific Biosciences exotic insider transaction detected
Van Oene Mark over three months ago via Macroaxis 
Acquisition by Van Oene Mark of 300000 shares of Pacific Biosciences subject to Rule 16b-3
Eidel Jeff over three months ago via Macroaxis 
Acquisition by Eidel Jeff of 600000 shares of Pacific Biosciences subject to Rule 16b-3
Marshall Mohr over three months ago via Macroaxis 
Exercise or conversion by Marshall Mohr of 35000 shares of Pacific Biosciences subject to Rule 16b-3
Valantine Hannah over six months ago via Macroaxis 
Acquisition by Valantine Hannah of 63015 shares of Pacific Biosciences subject to Rule 16b-3
William Ericson over six months ago via Macroaxis 
Acquisition or disposition of Pacific Biosciences securities by William Ericson
William Ericson over six months ago via Macroaxis 
Exercise or conversion by William Ericson of 25000 shares of Pacific Biosciences subject to Rule 16b-3
Farmer Michele over six months ago via Macroaxis 
Acquisition by Farmer Michele of 44800 shares of Pacific Biosciences subject to Rule 16b-3
Kim Susan G over six months ago via Macroaxis 
Sale by Kim Susan G of 1062 shares of Pacific Biosciences
Michael Hunkapiller over six months ago via Macroaxis 
Exercise or conversion by Michael Hunkapiller of 45686 shares of Pacific Biosciences subject to Rule 16b-3

Pacific Biosciences Predictive Daily Indicators

Pacific Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pacific Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Pacific Biosciences Forecast Models

Pacific Biosciences time-series forecasting models is one of many Pacific Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pacific Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Pacific Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pacific Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pacific shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Pacific Biosciences. By using and applying Pacific Stock analysis, traders can create a robust methodology for identifying Pacific entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(110.47) (119.19) 
EBITDA Margin 41.15  44.40 
Gross Margin 45.10  39.17 
Profit Margin 33.54  36.19 

Current Pacific Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pacific analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pacific analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
40.33Buy6Odds
Pacific Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Pacific analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pacific stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pacific Biosciences, talking to its executives and customers, or listening to Pacific conference calls.
Pacific Analyst Advice Details

Pacific Stock Analysis Indicators

Pacific Biosciences stock analysis indicators help investors evaluate how Pacific Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pacific Biosciences shares will generate the highest return on investment. By understating and applying Pacific Biosciences stock analysis, traders can identify Pacific Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow85947000.00
Logo U R LimglogosUSPACB.png
Common Stock Shares Outstanding204136000.00
Total Stockholder Equity790987000.00
DescriptionPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBios Systems, which conduct, monitor, and analyse biochemical sequencing reactions consumable prod
Total Cashflows From Investing Activities-678531000.00
Tax Provision-93649000.00
Property Plant And Equipment Net79121000.00
Retained Earnings-1218092000.00
Cash And Short Term Investments460725000.00
Retained Earnings Total Equity-1218092000.00
Cash460725000.00
CodePACB
Accounts Payable11002000.00
Net Debt493022000.00
50 Day M A7.7782
Total Current Liabilities83289000.00
Currency CodeUSD
Other Operating Expenses308676000.00
Non Current Assets Total901244000.00
Common Stock Total Equity221000.00
Non Currrent Assets Other1170000.00
Please check Your Equity Center. Note that the Pacific Biosciences information on this page should be used as a complementary analysis to other Pacific Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Pacific Stock analysis

When running Pacific Biosciences price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Is Pacific Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
2.1 B
Quarterly Revenue Growth YOY
(0.07) 
Return On Assets
(0.09) 
Return On Equity
(0.41) 
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Pacific Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.